iohexol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
iodine-containing contrast media 1461 66108-95-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • iohexol
An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
  • Molecular weight: 821.14
  • Formula: C19H26I3N3O9
  • CLOGP: -2.44
  • LIPINSKI: 3
  • HAC: 12
  • HDO: 8
  • TPSA: 199.89
  • ALOGS: -3.01
  • ROTB: 12

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 95 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 4597.21 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.16 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.50 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 26, 1985 FDA GE HEALTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urticaria 855.31 33.85 366 5111 135519 53208070
Pruritus 421.40 33.85 298 5179 293534 53050055
Contrast media reaction 401.15 33.85 73 5404 1010 53342579
Sneezing 390.61 33.85 116 5361 14556 53329033
Erythema 300.20 33.85 191 5286 156778 53186811
Extravasation 278.54 33.85 61 5416 2233 53341356
Throat irritation 209.45 33.85 89 5388 31592 53311997
Contrast media allergy 202.16 33.85 46 5431 2006 53341583
Throat tightness 165.54 33.85 68 5409 22148 53321441
Dyspnoea 113.44 33.85 209 5268 586023 52757566
Anaphylactic reaction 96.31 33.85 65 5412 58261 53285328
Anaphylactic shock 92.27 33.85 45 5432 21848 53321741
Chills 59.33 33.85 63 5414 104785 53238804
Chest discomfort 58.36 33.85 61 5416 99634 53243955
Hypersensitivity 57.53 33.85 88 5389 210577 53133012
Eye swelling 55.59 33.85 32 5445 21662 53321927
Local anaesthetic systemic toxicity 51.42 33.85 12 5465 584 53343005
Pharyngeal oedema 49.72 33.85 26 5451 14587 53329002
Paraesthesia oral 49.60 33.85 25 5452 13000 53330589
Aneurysm ruptured 47.40 33.85 11 5466 522 53343067
Fatigue 47.32 33.85 9 5468 730497 52613092
Drug ineffective 47.12 33.85 13 5464 817232 52526357
Patent ductus arteriosus 42.58 33.85 16 5461 4102 53339487
Laryngeal oedema 41.04 33.85 17 5460 5628 53337961
Papule 37.09 33.85 15 5462 4672 53338917
Anaphylactoid reaction 36.78 33.85 14 5463 3717 53339872
Cough 36.54 33.85 81 5396 256812 53086777
Eye pruritus 34.85 33.85 20 5457 13449 53330140
No adverse event 34.31 33.85 30 5447 39235 53304354

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urticaria 544.47 28.50 223 3910 59391 32450002
Contrast media reaction 305.14 28.50 58 4075 821 32508572
Sneezing 278.57 28.50 73 4060 4658 32504735
Pruritus 242.48 28.50 168 3965 128534 32380859
Erythema 208.62 28.50 130 4003 82975 32426418
Extravasation 201.17 28.50 47 4086 1856 32507537
Contrast media allergy 190.41 28.50 35 4098 407 32508986
Anaphylactic reaction 106.47 28.50 59 4074 30113 32479280
Anaphylactic shock 80.70 28.50 39 4094 14995 32494398
Chills 67.45 28.50 65 4068 78019 32431374
Rash maculo-papular 62.91 28.50 41 4092 27981 32481412
Throat tightness 60.11 28.50 26 4107 7740 32501653
Acute kidney injury 57.17 28.50 119 4014 293349 32216044
Throat irritation 51.35 28.50 25 4108 9753 32499640
Anaphylactoid shock 47.27 28.50 11 4122 425 32508968
Drug reaction with eosinophilia and systemic symptoms 46.21 28.50 36 4097 32449 32476944
Vomiting 45.15 28.50 95 4038 235462 32273931
Overlap syndrome 43.58 28.50 8 4125 92 32509301
Hypersensitivity 42.29 28.50 44 4089 57714 32451679
Eye pruritus 34.48 28.50 15 4118 4523 32504870
Nephropathy toxic 30.56 28.50 19 4114 11927 32497466
Eye swelling 29.08 28.50 17 4116 9555 32499838

Pharmacologic Action:

SourceCodeDescription
ATC V08AB02 VARIOUS
CONTRAST MEDIA
X-RAY CONTRAST MEDIA, IODINATED
Watersoluble, nephrotropic, low osmolar X-ray contrast media
FDA MoA N0000010258 X-Ray Contrast Activity
MeSH PA D003287 Contrast Media
MeSH PA D064907 Diagnostic Uses of Chemicals
FDA EPC N0000180185 Radiographic Contrast Agent
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:37338 radioopaque media
CHEBI has role CHEBI:78298 environmental contaminants

Drug Use (View source of the data)

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.73 acidic
pKa2 11.33 acidic
pKa3 12.2 acidic
pKa4 13.65 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4018251 VUID
N0000146581 NUI
D01817 KEGG_DRUG
4018251 VANDF
C0022005 UMLSCUI
CHEBI:31709 CHEBI
CHEMBL1200455 ChEMBL_ID
D007472 MESH_DESCRIPTOR_UI
DB01362 DRUGBANK_ID
4848 INN_ID
4419T9MX03 UNII
3730 PUBCHEM_CID
5956 RXNORM
4904 MMSL
d01456 MMSL
000673 NDDF
109218004 SNOMEDCT_US
395751002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
OMNIPAQUE HUMAN PRESCRIPTION DRUG LABEL 1 0407-1401 INJECTION, SOLUTION 140 mg INTRAVENOUS NDA 28 sections
OMNIPAQUE HUMAN PRESCRIPTION DRUG LABEL 1 0407-1411 INJECTION, SOLUTION 180 mg ORAL NDA 28 sections
OMNIPAQUE HUMAN PRESCRIPTION DRUG LABEL 1 0407-1412 INJECTION, SOLUTION 240 mg INTRAVENOUS NDA 28 sections
OMNIPAQUE HUMAN PRESCRIPTION DRUG LABEL 1 0407-1412 INJECTION, SOLUTION 240 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1413 INJECTION, SOLUTION 300 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1414 INJECTION, SOLUTION 350 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1414 INJECTION, SOLUTION 350 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1414 INJECTION, SOLUTION 350 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1414 INJECTION, SOLUTION 350 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1414 INJECTION, SOLUTION 350 mg INTRAVENOUS NDA 28 sections
Omnipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-1414 INJECTION, SOLUTION 350 mg INTRAVENOUS NDA 28 sections
OMNIPAQUE HUMAN PRESCRIPTION DRUG LABEL 1 0407-1415 SOLUTION 9 mg ORAL NDA 28 sections
OMNIPAQUE HUMAN PRESCRIPTION DRUG LABEL 1 0407-1416 SOLUTION 12 mg ORAL NDA 28 sections
ORALTAG HUMAN PRESCRIPTION DRUG LABEL 1 54702-501 FOR SOLUTION 4.50 g ORAL NDA 19 sections